The FDA has dropped a bomb on Eli ... in support of the PD-1 inhibitor do not meet the criteria for foreign data filed in support of a marketing application in the US. Lilly licenses sintilimab ...
FDA advisors have voted against approval of Eli Lilly and Innovent Biologics' cancer immunotherapy sintilimab, undermining hopes of a new, lower-priced option in the PD-1/PD-L1 inhibitor class.
Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.
Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...
In obesity, Lilly removed a dual amylin calcitonin receptor agonist (DACRA) from its phase 1 pipeline. Lilly got into DACRAs by partnering with KeyBioscience in 2017. At one time, the Big Pharma was ...
Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...
Not long after reporting phase 2 data for one of its obesity candidates that appeared to put it on par with Eli Lilly’s Zepbound ... small molecule GLP-1 receptor agonist, a once-daily oral ...
A dozen GLP-1 receptor agonists and coagonists ... that trial participants who received retatrutide (Eli Lilly) — an investigational triple agonist that activates the glucose-dependent ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback